RU98118019A - PHARMACEUTICAL PREPARATIONS OF Slow-Release, Containing Misolastins - Google Patents

PHARMACEUTICAL PREPARATIONS OF Slow-Release, Containing Misolastins

Info

Publication number
RU98118019A
RU98118019A RU98118019/14A RU98118019A RU98118019A RU 98118019 A RU98118019 A RU 98118019A RU 98118019/14 A RU98118019/14 A RU 98118019/14A RU 98118019 A RU98118019 A RU 98118019A RU 98118019 A RU98118019 A RU 98118019A
Authority
RU
Russia
Prior art keywords
sustained release
pharmaceutical preparation
misolastine
organic acid
paragraphs
Prior art date
Application number
RU98118019/14A
Other languages
Russian (ru)
Other versions
RU2173997C2 (en
Inventor
Маривонн Шарье
Гэрет Люис
Жан Монтель
Original Assignee
Синтелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9602662A external-priority patent/FR2745500B1/en
Application filed by Синтелябо filed Critical Синтелябо
Publication of RU98118019A publication Critical patent/RU98118019A/en
Application granted granted Critical
Publication of RU2173997C2 publication Critical patent/RU2173997C2/en

Links

Claims (7)

1. Фармацевтический препарат замедленного высвобождения, содержащий мизоластин, отличающийся тем, что он содержит ядро, образованное таблеткой замедленного высвобождения, содержащей мизоластин в сочетании с жировой основой и органической кислотой, причем указанная таблетка покрыта оболочкой.1. A sustained release pharmaceutical preparation containing misolastine, characterized in that it comprises a core formed by a sustained release tablet containing misolastine in combination with a fatty base and an organic acid, said tablet being coated. 2. Фармацевтический препарат замедленного высвобождения по п. 1, отличающийся тем, что массовое соотношение между мизоластином и органической кислотой составляет 0,3-1. 2. The pharmaceutical preparation for sustained release according to claim 1, characterized in that the mass ratio between misolastine and organic acid is 0.3-1. 3. Фармацевтический препарат замедленного высвобождения по п. 1 или 2, отличающийся тем, что жировая основа изготовлена из гидрогенизированного касторового масла или из гидрогенизированных лецитинов, или из длинно-цепочечных жирных кислот, или из триглицеридов, этерифицированных жирными кислотами со средней длиной цепи. 3. A sustained release pharmaceutical preparation according to claim 1 or 2, characterized in that the fat base is made from hydrogenated castor oil or from hydrogenated lecithins, or from long chain fatty acids, or from triglycerides esterified with medium chain length fatty acids. 4. Фармацевтический препарат замедленного высвобождения по любому из пп. 1-3, отличающийся тем, что органическая кислота выбрана из малеиновой, винной, яблочной, фумаровой, молочной, лимонной, адипиновой и янтарной кислот в форме рацематов или изомеров. 4. The pharmaceutical preparation for sustained release according to any one of paragraphs. 1-3, characterized in that the organic acid is selected from maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acids in the form of racemates or isomers. 5. Фармацевтический препарат замедленного высвобождения по любому из пп. 1-4, отличающийся тем, что органическая кислота представляет собой L-винную кислоту. 5. The pharmaceutical preparation for sustained release according to any one of paragraphs. 1-4, characterized in that the organic acid is an L-tartaric acid. 6. Фармацевтический препарат замедленного высвобождения по п. 5, отличающийся тем, что соотношение между мизоластином и L-винной кислотой составляет 0,5. 6. The pharmaceutical preparation for sustained release according to claim 5, characterized in that the ratio between misolastine and L-tartaric acid is 0.5. 7. Препарат по любому из пп. 1-6, отличающийся тем, что он содержит 1-25 мг мизоластина. 7. The drug according to any one of paragraphs. 1-6, characterized in that it contains 1-25 mg of misolastine.
RU98118019/14A 1996-03-04 1997-02-28 Retarded-release pharmaceutical preparations including misolastin RU2173997C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR96/02662 1996-03-04
FR9602662A FR2745500B1 (en) 1996-03-04 1996-03-04 SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING MIZOLASTINE

Publications (2)

Publication Number Publication Date
RU98118019A true RU98118019A (en) 2000-07-20
RU2173997C2 RU2173997C2 (en) 2001-09-27

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98118019/14A RU2173997C2 (en) 1996-03-04 1997-02-28 Retarded-release pharmaceutical preparations including misolastin

Country Status (35)

Country Link
US (2) US6165507A (en)
EP (1) EP0906101B1 (en)
JP (2) JP2000512617A (en)
KR (1) KR100369888B1 (en)
CN (1) CN1112929C (en)
AR (1) AR006082A1 (en)
AT (1) ATE219365T1 (en)
AU (1) AU725494B2 (en)
BG (1) BG63451B1 (en)
BR (1) BR9707827A (en)
CA (1) CA2247405C (en)
CO (1) CO4780020A1 (en)
CY (1) CY2293B1 (en)
CZ (1) CZ291418B6 (en)
DE (1) DE69713505T2 (en)
DK (1) DK0906101T3 (en)
EE (1) EE03511B1 (en)
ES (1) ES2177942T3 (en)
FR (1) FR2745500B1 (en)
HK (1) HK1017999A1 (en)
HU (1) HU227472B1 (en)
IL (1) IL126050A (en)
IN (1) IN187739B (en)
NO (1) NO315841B1 (en)
NZ (1) NZ331947A (en)
OA (1) OA10854A (en)
PL (1) PL189813B1 (en)
PT (1) PT906101E (en)
RU (1) RU2173997C2 (en)
SK (1) SK282112B6 (en)
TR (1) TR199801574T2 (en)
TW (1) TW491711B (en)
UA (1) UA49004C2 (en)
WO (1) WO1997032584A1 (en)
ZA (1) ZA971830B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (en) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd Sustained release tablet
EP1322158B1 (en) * 2000-10-02 2012-08-08 USV Ltd. Sustained release pharmaceutical compositions containing metformin and method of their production
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CA2518442A1 (en) * 2003-03-04 2004-09-16 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (en) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
BRPI0916689A2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical stabilized pharmaceutical composition, solid preparation, and methods for stabilizing a pharmaceutical composition, and for stabilizing a solid preparation.
JP5744412B2 (en) * 2010-03-26 2015-07-08 テバ製薬株式会社 Furosemide formulation
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (en) * 1985-09-11 1987-10-30 Synthelabo BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
JPH0776172B2 (en) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 Matrice locks
JPS62283926A (en) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd Long-acting composition of nicardipine hydrochloride
DE3812799A1 (en) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh ORGANIC PREPARATION FOR THE PURPOSES OF AN ACTUATED ACTIVE INGREDIENTS AND METHOD OF PREPARING THEM
JP3195391B2 (en) * 1991-11-14 2001-08-06 エスエス製薬株式会社 Sustained-release trapidil tablets
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (en) * 1993-07-09 1996-10-04 Applied Pharma Res PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED
JPH07112932A (en) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc Sustained release medicine preparation

Similar Documents

Publication Publication Date Title
RU98118019A (en) PHARMACEUTICAL PREPARATIONS OF Slow-Release, Containing Misolastins
NZ322467A (en) Use of epinastine in the treatment of pain
RU2006128796A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SIDE EFFECTS AND IDIOPATHIC SYNDROMES Caused by OPIOIDES
NZ515911A (en) Implantable gel compositions and method of manufacture
CA2191645A1 (en) Pharmaceutical composition comprising l-carnitine or an alkanoyl l-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and the treatment of lipid metabolism disorders
CA2149242A1 (en) Quinuclidine Derivative for Treatment of Inflammatory and Gastrointestinal Disorders
AU2681300A (en) Solid oral dosage form containing an enhancer
EP0668073A3 (en) Polyester matrix for a pharmaceutical sustained-release preparation.
HUT53634A (en) Herbicides comprising aromatic carboxylic acid derivatives as active ingredient and process for producing the active ingredients
RU94046413A (en) Pharmaceutical composition containing cyclosporine derivative and its preparing
RU93004860A (en) HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PRODUCTION, USE AND PHARMACEUTICAL COMPOSITION
JP2007182451A (en) Sustained-release pharmaceutical formulation containing mizolastine
CA2366841A1 (en) Tolperisone-containing pharmaceutical preparation for oral administration
RU93058535A (en) TABLET CONTAINING KOLESTIPOL HYDROCHLORIDE AND METHOD FOR PRODUCING IT
CA2255052A1 (en) Sustained release preparation of prostaglandin i derivatives
NO177774C (en) Process for the preparation of a composition suitable for administration of a substantially water-insoluble active ingredient
EE9700078A (en) Pyrimido (1,2-a) indoles, process for their preparation, use in the manufacture of medicaments, medicaments containing these indoles and carboxylic acids used in the manufacture of indoles and method for their preparation
JP2752792B2 (en) Novel composition containing selegiline
RU93054754A (en) 6-HETEROCYCLO-4-AMINO-1,3,4,5-TETRAHYDROBENZ / CD / INDOLS, THEIR APPLICATION FOR THE TREATMENT OF SUSPENSION AND MORPHANIZED PHENOMENA, PHARMACEUTICAL COMPOSITION, THE METHOD OF THEIR
HUT54106A (en) Process for producing carboxylic acid amides and pharmaceutical compositions comprising such active ingredient
CA2186767A1 (en) Fractionation of triglyceride oils
RU92016533A (en) Arylalkyl ethers of 4,5-dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene carboxylic acid possessing therapeutic activity, method for their preparation, pharmaceutical composition
CA2223695A1 (en) Dicarboxylic acids as an animal feed ingredient
HUT47124A (en) Process for producing pharmaceutical compositions comprising organic platinum complex as active ingredient and the active ingredients
HUT52388A (en) Process for producing pharmaceutical compositions comprising unsaturated fatty acids and selenium as active ingredient